Table 1.

Characteristics of a subset^a of men from the placebo arm of PCPT, by aspirin use^b and statins use^b

	Aspirin Use		Statins Use
	No	Yes	No	Yes
N	139	218	242	115
Age at end-of-study biopsy, median	69	70	69	71
Racec, %
White	96	96	95	97
Non-white	4	4	5	3
College educationc, %	60	48	54	50
Diabetesc, %	6	6	4	9
BMIc (kg/m2), median	26.7	27.4	26.9	27.3
Smoking statusc, %
Current	8	8	10	3
Former	48	66	56	64
Never	44	27	34	32
Pack-years of smokingc, median	21.5	23.1	21.5	23.1
Physical activityc, %
Sedentary	19	24	21	23
Light	12	17	14	16
Moderate	58	46	53	45
Very active	11	13	11	16
Missing	1	0	0	0
Daily intakec, median
Energy (kcal)	1930	2094	2115.1	1860.5
Vegetables (servings/day)	1.9	2.0	1.8	2.1
Total fat (g)	67.6	74.5	77.9	62.3
Polyunsaturated fatty acids (g)	14.0	15.4	15.4	13.0
Total protein (g)	78.6	87.9	88.0	78.0
Red meat (servings/week)	3.5	3.9	4.0	3.4
Alcoholic beverages (drinks/day)	0.3	0.2	0.4	0.1
PSA at biopsy (ng/mL), median	1.7	1.4	1.6	1.3
Prostate cancer diagnosis at end-of-study biopsy, %	15	19	16	21

^aFrom a case-control study of LUTS nested in the placebo arm of PCPT (5). The men did not have a clinical indication for biopsy.

^bReported at trial entry or during the 7 years of the trial

^cReported at trial entry

PCPT, Prostate Cancer Prevention Trial; BMI, body mass index; PSA, prostate-specific antigen